Immunovia AB (publ) reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was SEK 0.103 million compared to SEK 0.038 million a year ago. Revenue was SEK 0.108 million compared to SEK 0.097 million a year ago. Net loss was SEK 33.73 million compared to SEK 49.26 million a year ago. Basic loss per share from continuing operations was SEK 1.49 compared to SEK 2.18 a year ago. Diluted loss per share from continuing operations was SEK 1.49 compared to SEK 2.18 a year ago.
For the six months, sales was SEK 0.285 million compared to SEK 0.161 million a year ago. Revenue was SEK 0.309 million compared to SEK 0.226 million a year ago. Net loss was SEK 77.84 million compared to SEK 72.71 million a year ago. Basic loss per share from continuing operations was SEK 3.44 compared to SEK 3.21 a year ago. Diluted loss per share from continuing operations was SEK 3.44 compared to SEK 3.21 a year ago.